GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing - GBI Research Reports

GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing

GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing - GBI Research Reports
GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing
Published Nov 01, 2011
143 pages — Published Nov 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing which provides insights in to the technical and commercial importance of G protein coupled receptors, which are the most important category of receptors in the human body. The report provides a scientific understanding of GPCRs and details the novel research methods being employed in the research of new targets and molecules that can be more effective in treating many indications. A special note on Orphan GPCRs and ways to de-orphanize them is followed by a detailed pipeline analysis to understand the therapeutic classes and indications that are being targeted through GPCRs. The report provides an in-depth analysis of the competitive landscape, including the profiling of top companies and licensing agreements involving GPCR molecules and platform technologies.

Scope

The scope of this report includes -
- Detailed technical understanding of G protein coupled receptors
- Dedicated sections on Novel research methods being used to improve the GPCR targeted drug discovery and development process
- Understanding of Orphan GPCRs, its importance and novel methods to locate ligands and de-orphanize these receptors
- Pipeline analysis of products at various stages of development targeting receptors classified as GPCRs, including identification of major therapeutic areas and indications
- Analysis and review of important strategic partnerships and licensing agreements in the area of GPCR drug discovery and development
- The report also covers information on the leading market players and the competitive landscape, including specialist companies which have proprietary GPCR platform technology as well as major companies with molecules in not only the NDA Filed stage but also in Phase III

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop business strategies by understanding the trends shaping and driving research in the field of GPCRs
- Understand the potential areas of application for GPCR therapies.
- Identify key molecules targeting GPCRs in development based on the therapy.
- Identify the key players investing in GPCR platform technologies
- Optimize your R&D pipeline through identification of novel technologies being used in GPCR research to improve the drug discovery process
- Identify emerging players with a potentially strong product portfolio of molecules targeting GPCRs and create effective counter-strategies to gain a competitive advantage.
- Whats the next big thing in GPCR research? Identify, understand and capitalize.

  
Source:
Document ID
GBIHC137MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents48
  List of Tables82
  List of Figures102
GPCRs in Drug Discovery Introduction121
  GBI Research Report Guidance121
GPCRs in Drug Discovery Overview1313
  Introduction131
  GPCR in the Human Genome141
    Introduction141
    The Traditional Classification System141
    The GRAFS Classification System151
      The Glutamate Receptor Family151
      The Rhodopsin Receptor Family161
      The Adhesion Family161
      The Frizzled/Taste2 Receptor Family161
      The Secretin Family161
  Structure of GPCRs171
    General Structure171
    Importance of the 7TM171
      Different Structures of the TM171
      TM Loop Formation171
      Structures of the TM Core and Disulphide Bonds171
  Structure of G-proteins181
  Coupling to G-proteins191
    Introduction191
    The Signal Transduction Pathways Involving GPCR191
      The cAMP Signal Pathway192
      The Phosphatidylinositol Signal Pathway211
      The G12/13 Coupled Receptors and RhoGEF Proteins211
  Second Messengers in the GPCR System221
    Introduction to Second Messengers221
    Cyclic Adenosine Monophosphate (cAMP)221
    Cyclic Guanosine Monophosphate (cGMP)231
    Diacylglycerol (DAG)231
    Inositol 1, 4, 5-triphosphate (IP3)241
    Calcium Ions (Ca2+ )241
  Post-Translational Modifications251
    Glycosylation, Palmitoylation and Phosphorylation251
    GPCR Desensitization251
GPCRs in Drug Discovery Novel Research Methods in GPCR Drug Discovery2610
  Introduction261
  Structure-Based Research in GPCR261
    Introduction261
    New Avenues261
      Computational Modeling261
      X-Ray Crystallography261
      Alternative Biophysical Approaches271
    Case Studies271
      The Scripps Research Institute271
      Receptos Inc.271
  Fragment-Based Drug Discovery281
    Introduction281
    New Avenues281
    Case Study281
      Heptares Therapeutics281
  Ligand-Induced Selective Signaling (LiSS)281
    Introduction281
    New Avenues291
      Studies in Gonadotropin-Releasing Hormone (GnRH)291
      Biased Ligands291
    Case Study291
      Trevena Inc.291
  Allosterism and GPCRs291
    Introduction291
    New Avenues301
      Select Current Allosteric Modulators in Research301
      Allosteric Modulators of GPCR G Protein Coupling: Pepducins301
      Bitopic or Dualsteric Ligands301
      Collateral Efficacy and Permissive Antagonism311
    Case Studies311
      Addex Pharmaceuticals Ltd.311
      Anchor Therapeutics311
      Domain Therapeutics321
  GPCR Dimerization321
    Introduction321
    Need to Form Dimers321
      G Protein Activation Facilitation321
      Control of Cell Surface Delivery321
    New Avenues321
      Currently Employed Biochemical Techniques: Resonance Energy Transfer (RET)321
      PathHunter GPCR Dimerization System321
      Tag-lite Technology331
    Case Studies331
      DiscoveRx331
      Cisbio Bioassays331
  GPCR Oligomerization341
    Introduction341
    Classification of Oligomers341
    New Avenues351
      Changes in Ligand Recognition351
      Influence on G Protein Coupling351
      Transactivation351
    Case Studies351
      Cara Therapeutics351
      Dimerix Bioscience351
GPCRs in Drug Discovery Orphan GPCRs366
  Introduction361
    Orphan GPCRs in the GRAFS Classification System361
    Orphan GPCRs in the Traditional Classification System371
  Current Methods Used in De-orphanization381
    Introduction381
    Reverse Pharmacology391
    Orphan Receptor Strategy401
    Phylogenetic Analysis and Chemogenomics401
  Functional Assays for De-orphanization401
    Introduction401
    G protein-dependent Assays401
    Recent G protein-independent Assays411
      Extracellular-Regulated Kinase (ERK) Activation Cell-based Assay411
      GPCR Internalization411
GPCRs in Drug Discovery Pipeline Analysis by Therapeutic Class4243
  Central Nervous System461
    Introduction461
    Pipeline Profile461
    Major Indications475
  Oncology521
    Introduction521
    Pipeline Profile521
    Major Indications533
  Cardiovascular System561
    Introduction561
    Pipeline Profile561
    Major Indications573
  Metabolic Disorders601
    Introduction601
    Pipeline Profile601
    Major Indications613
  Gastrointestinal Disorders641
    Introduction641
    Pipeline Profile641
    Major Indications652
  Respiratory Diseases671
    Introduction671
    Pipeline Profile671
    Major Indications683
  Immunology711
    Introduction711
    Pipeline Profile711
    Major Indications722
  Women s Health741
    Introduction741
    Pipeline Profile741
    Major Indications753
  Ophthalmology781
    Introduction781
    Pipeline Profile781
    Major Indications793
  Genito-Urinary System and Sex Hormones821
    Introduction821
    Pipeline Profile821
    Major Indications832
GPRCs in Drug Discovery Pipeline Analysis by Indications8533
  Diabetes881
    Introduction881
    Pipeline Profile881
    Analysis of Major Targets892
  Parkinson s Disease911
    Introduction911
    Pipeline Profile911
    Analysis of Major Targets922
  Pain941
    Introduction941
    Pipeline Profile941
    Analysis of Major Targets952
  Schizophrenia971
    Introduction971
    Pipeline Profile971
    Analysis of Major Targets982
  Obesity1001
    Introduction1001
    Pipeline Profile1001
    Analysis of Major Targets1012
  Hypertension1031
    Introduction1031
    Pipeline Profile1031
    Analysis of Major Targets1042
  Asthma1061
    Introduction1061
    Pipeline Profile1061
    Analysis of Major Targets1072
  Prostate Cancer1091
    Introduction1091
    Pipeline Profile1091
    Analysis of Major Targets1102
  Chronic Obstructive Pulmonary Disease (COPD)1121
    Introduction1121
    Pipeline Profile1121
    Analysis of Major Targets1132
  Glaucoma1151
    Introduction1151
    Pipeline Profile1151
    Analysis of Top Targets1162
GPCRs in Drug Discovery Competitive Landscape11816
  GPCRs in Drug Discovery Major Companies With GPCR Platform Technology1181
    Heptares Therapeutics Ltd.1181
      Company Overview1181
    Receptos Inc.1181
      Company Overview1181
    7TM Pharma A/S1191
      Company Overview1191
    Dimerix Biosciences Pvt. Ltd.1191
      Company Overview1191
    Trevena, Inc.1191
      Company Overview1191
    Cara Therapeutics, Inc.1201
      Company Overview1201
    Addex Pharmaceuticals1201
      Company Overview1201
    Anchor Therapeutics1211
      Company Overview1211
    Domain Therapeutics1211
      Company Overview1211
    Euroscreen S.A.1221
      Company Overview1221
    Omeros Corporation1221
      Company Overview1221
    Arena Pharmaceuticals1231
      Company Overview1231
    Compugen, Ltd.1231
      Company Overview1231
    Tranzyme Pharma, Inc.1241
      Company Overview1241
    Oxagen Limited1251
      Company Overview1251
    Prosarix Ltd.1251
      Company Overview1251
    Acadia Pharmaceuticals Inc.1261
      Company Overview1261
    Actelion Ltd.1271
      Company Overview1271
    AcurePharma AB1271
      Company Overview1271
    DiscoveRx1271
      Company Overview1271
  GPCRs in Drug Discovery Top 5 Companies as per Number of Molecules in NDA Filed and in Phase III1281
    Merck &Co., Inc.1281
      Company Overview1282
    Novartis AG1301
      Company Overview1301
    Pfizer Inc.1311
      Company Overview1311
    Eli Lilly and Company1321
      Company Overview1321
    Johnson and Johnson1331
      Company Overview1331
GPCRs in Drug Discovery Strategic Consolidations1345
  AstraZeneca Enters Into Co-Development Agreement With Heptares1341
  Heptares Therapeutics Enters Into Option Licensing Agreement With Shire For Adenosine A2A1341
  Dimerix Bioscience Enters Into Research Agreement With Takeda Cambridge1351
  Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharmaceutical Company Ltd.1351

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing" Nov 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/GPCRs-in-Drug-Discovery-Efforts-to-De-Orphanize-Novel-GPCR-Targets-are-Increasing-2115-286>
  
APA:
GBI Research Reports. (2011). GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing Nov 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/GPCRs-in-Drug-Discovery-Efforts-to-De-Orphanize-Novel-GPCR-Targets-are-Increasing-2115-286>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.